Clinical trials: Ductus
Respiratory Distress Syndrome, Newborn, Patent Ductus Arteriosus
Optimal Dose of Surfactant for Preterm Infants With Respiratory Distress Syndrome
In preterm infants with neonatal respiratory distress syndrome (RDS), exogenous pulmonary surfactant(PS) replacement therapy is one of the most important therapeutic breakthrough to reduce neonatal incidences of bronchopulmonary…
- Conditions
- Respiratory Distress Syndrome, Newborn, Patent Ductus Arteriosus, Bronchopulmonary Dysplasia, Preterm
- Trial name
- NCT04984057
- Testing
- PS is stopped when the pressure is equal between bPDA and aPDA., PS is given according to the 2019 European RDS management guideline
- Where
- China
- Volunteers
- 300 people
- Sponsor
- Daping Hospital and the Research Institute of Surgery of the Third Military Medical University
Infant, Premature, Congenital Heart Disease
Splanchnic and Renal Tissue Oxygenation During Enteral Feedings in Neonates With Patent Ductus Arteriosus
Patent ductus arteriosus (PDA) is a common problem in the neonatal intensive care unit and can be secondary to prematurity or congenital heart disease (CHD).
- Conditions
- Infant, Premature, Congenital Heart Disease, Patent Ductus Arteriosus, Necrotizing Enterocolitis
- Trial name
- NCT03551600
- Testing
- Near-infrared spectroscopy (NIRS)
- Where
- 3 sites in United States
- Volunteers
- 64 people
- Sponsor
- University of Utah
Patent Ductus Arteriosus in Preterm Infants
Noninvasive Hemodynamics Assessment of Preterms With Successful Medical Closure of PDA
The aim of our study was to use Electrical Cardiometry EC to monitor hemodynamic alternations during pharmacological closure of hemodynamically significant patent ductus arteriosus (hsPDA) in preterm neonates
- Trial name
- NCT06606015
- Testing
- I.V Paracetamol., Echocardiography., Electrical Cardiometry
- Where
- Egypt
- Volunteers
- 43 people
- Sponsor
- Tanta University
Patent Ductus Arteriosus, Prematurity
Early Versus Late Use of Ibuprofen for Patent Ductus Arteriosus (PDA) Closure
The primary objective is to evaluate the Patent Ductus Arteriosus (PDA) closure rate of early vs. late use of Ibuprofen (Ibu). The investigators believe that early use of Ibu will have a higher PDA closure rate than later use of…
- Trial name
- NCT00833365
- Testing
- Ibuprofen
- Where
- United States
- Volunteers
- 15 people
- Sponsor
- University of Utah
Patent Ductus Arteriosus
Clinical Profile of Neonates Having Patent Ductus Arteriosus
The study aims to evaluate the clinical presentation and course of PDA diagnosed at neonatal period in the neonatology unit of Assiut University Hospital for Children.
- Trial name
- NCT04672629
- Testing
- echocardiography
- Volunteers
- 30 people
- Sponsor
- Assiut University
Preterm, Ductus Arteriosus
Dynamic Changes of Ductus Arteriosus in < 31 Weeks Preterm Infants: an Observational Study
The ductus arteriosus quickly closes itself. is an important channel connecting the maternal fetal circulation before birth. After birth, this ductus arteriosus generally no longer has a physical function, so ductus arteriosus…
- Trial name
- PDA (NCT06950164)
- Testing
- observation group, control group
- Where
- China
- Volunteers
- 200 people
- Sponsor
- Daping Hospital and the Research Institute of Surgery of the Third Military Medical University
Ductus Arteriosus
The Role of Fetal Ductus Arteriosus in Predicting Spontaneous Labour at Term
The exact mechanism stimulating the parturition in humans is still relatively unknown. Prostaglandins, by mediating cervical ripening and early stimulation of myometrial contractions, are likely to play a major role in the…
- Trial name
- NCT03073460
- Testing
- Ultrasound examination
- Sponsor
- Unity Health Toronto
Patent Ductus Arterioses
The Impact of Platelet Functions on Spontaneous Ductal Closure in Preterm Infants
Although thrombocytopenia has been reported as a risk factor for patent ductus arterioses, there is lack of data on the function of platelets in ductal closure.
- Trial name
- PFA100 (NCT02010879)
- Where
- Turkey (Türkiye)
- Volunteers
- 80 people, healthy volunteers welcome
- Sponsor
- Ankara University
Oral Ibuprofen Prophylaxis in Very Low Birth Weight Infants
Oral Ibuprofen Prophylaxis for Patent Ductus Arterioses in Very Extremely Low Birth Weight Infants
Patent ductus arterioses (PDA) is a major morbidity in preterm infants, especially in extremely premature infants less than 28 weeks.
- Trial name
- OIP (NCT01400737)
- Testing
- ibuprofen
- Where
- Turkey (Türkiye)
- Volunteers
- 200 people
- Sponsor
- Zekai Tahir Burak Women's Health Research and Education Hospital
Patent Ductus Arteriosus in Preterm Infants
The Effectiveness of Paracetamol Versus Ibuprofen in Management of Patent Ductus Arteriosus in Preterm Neonates
This study aims to find and compare the effectiveness of paracetamol and ibuprofen in the closure of patent ductus arteriosus in preterm neonates.
- Trial name
- NCT06601114
- Testing
- Paracetamol Group, Ibuprofen group
- Where
- Pakistan
- Volunteers
- 254 people
- Sponsor
- Arooj Khan
Patent Ductus Arteriosus
Treating the Resistant Patent Ductus Arteriosus (PDA)
Persistent postnatal ductal patency may have significant adverse hemodynamic effects, frequently necessitating therapeutic intervention in order to facilitate ductal closure.
- Trial name
- NCT00616382
- Testing
- Indomethacin, Pentoxifylline
- Where
- Israel
- Volunteers
- 68 people, healthy volunteers welcome
- Sponsor
- Shaare Zedek Medical Center
Patent Ductus Arteriosus
Safety and Efficacy of Ibuprofen in Term Newborns With Patent Ductus Arteriosus (PDA)
The aim of current study is to evaluate the efficacy and safety of oral Ibuprofen in term 20-28 days old newborn referred to Bandarabbas children' hospital in 2011.
- Trial name
- NCT01511887
- Testing
- Oral Ibuprofen
- Where
- Iran
- Volunteers
- 40 people
- Sponsor
- Hormozgan University of Medical Sciences
Cardiovascular Diseases, Heart Diseases
Reproduction and Survival After Cardiac Defect Repair
To create a registry of all Oregon children undergoing surgical repair of congenital heart disease since 1958 in order to determine mortality, morbidity, and disability after surgery and to assess the safety of pregnancy in women…
- Conditions
- Cardiovascular Diseases, Heart Diseases, Defect, Congenital Heart, Aortic Valve Stenosis
- Trial name
- NCT00005190
- Sponsor
- National Heart, Lung, and Blood Institute (NHLBI)
Patent Ductus Arteriosus, Preterm Infant
Randomized Controlled Trial to Evaluate the Safety and Efficacy of Acetaminophen in Preterm Infants Used in Combination With Ibuprofen for Closure of the Ductus Arteriosus
The purpose of the present study is to determine whether treatment of hemodynamically significant patent ductus arteriosus with a combined therapy of intravenous Ibuprofen and oral acetaminophen has higher success rate in closing…
- Conditions
- Patent Ductus Arteriosus, Preterm Infant, Bronchopulmonary Dysplasia
- Trial name
- NCT03701074
- Testing
- Ibuprofen and acetaminophen
- Where
- United States
- Volunteers
- 1 people
- Sponsor
- University of South Alabama
Patent Ductus Arteriosus
Acetaminophen vs Indomethacin in Treating hsPDA
The purpose of this study is to see if acetaminophen (Tylenol) is as effective as indomethacin in closing patent ductus arteriosus in premature infants.
- Trial name
- NCT03537144
- Testing
- Indomethacin, Acetaminophen
- Where
- 3 sites in United States
- Volunteers
- 37 people
- Sponsor
- University of Tennessee
Patent Ductus Arteriosus
Early Ibuprofen Treatment of Patent Ductus Arteriosus (PDA) in Premature Infants (TRIOCAPI)
Very premature infants with a large ductus, selected by an early echocardiogram, will receive either ibuprofen or placebo before 12 hours of life.
- Trial name
- TRIOCAPI (NCT01630278)
- Testing
- Ibuprofen
- Where
- 11 sites in France
- Volunteers
- 363 people
- Sponsor
- Nantes University Hospital
Patency of the Ductus Arteriosus
Study of Thoracic Ultrasound As a Response to the Closure of Hemodynamically Significant Patent Ductus Arteriosus in Premature Infants
The diagnostic hypothesis is based on the evidence that, while the functional closure of the PDA (Patent Ductus Arteriosus) occurs within a few hours after birth, anatomical closure may take several weeks.
- Trial name
- LUNG PDA (NCT06627374)
- Testing
- Patent Ductus Arteriosus in neonates
- Where
- Italy
- Volunteers
- 50 people
- Sponsor
- Fondazione Policlinico Universitario Agostino Gemelli IRCCS
Bronchopulmonary Dysplasia (BPD)
No Treatment Versus Oral Ibuprofen Treatment for Patent Ductus Arteriosus in Preterm Infants
The purpose of this study is to evaluate the efficacy and safety of no treatment compared with ibuprofen treatment for patent ductus arteriosus in preterm infants.
- Trial name
- NCT02128191
- Testing
- Oral ibuprofen, Normal saline
- Where
- South Korea
- Volunteers
- 142 people
- Sponsor
- Samsung Medical Center
Ductus Arteriosus, Patent
Alternative Paracetamol Treatments for the Neonate With a hsPDA
Early targeted treatment of a hemodynamically significant patent ductus arteriosus (hsPDA) during the first week of life in preterm neonates is often recommended.
- Trial name
- NCT03604796
- Testing
- Rectal Solution, Intravenous Infusion
- Where
- Israel
- Volunteers
- 80 people
- Sponsor
- Shaare Zedek Medical Center
Ductus Arteriosus, Patent
Analysis of the Impact of Patent Ductus Arteriosus on Brain Function in Preterm Neonates: Multimodal Approach Integrating EEG-NIRS, Ultrasound and Clinical Data
This project corresponds to the main field of research of the investigators's laboratory concerning analysis of cerebral electrometabolic and haemodynamic activity in neonates.
- Trial name
- NNP-MULTIMODAL (NCT02803671)
- Testing
- TFU-NIRS, NIRS, EEG
- Where
- France
- Volunteers
- 51 people, healthy volunteers welcome
- Sponsor
- Centre Hospitalier Universitaire, Amiens